Successful reversal of acute vascular rejection in a renal allograft with combined mycophenolate mofetil and tacrolimus as primary immunotherapy

Nasimul Ahsan, Michael J. Holman, Douglas A. Katz, Catherine S. Abendroth, Harold C. Yang

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

Despite the use of newer immunosuppressive drugs, early allograft rejection is still a major cause of graft loss and diminished graft survival. The pathological picture of acute interstitial rejection usually responds to high dose steroids, whereas the treatment of acute vascular (AVR) rejection characterized by an intense vasculitis and/or endotheliolitis is more formidable. The use of newer monoclonal antibodies specific for T lymphocytes and their subsets has only been occasionally successful in reversing AVR. Here we report a case of successful reversal of acute vascular renal allograft rejection with mycophenolate mofetil (MMF) and tacrolimus as primary therapy.

Original languageEnglish (US)
Pages (from-to)94-97
Number of pages4
JournalClinical Transplantation
Volume11
Issue number2
StatePublished - Apr 1 1997

All Science Journal Classification (ASJC) codes

  • Transplantation

Fingerprint Dive into the research topics of 'Successful reversal of acute vascular rejection in a renal allograft with combined mycophenolate mofetil and tacrolimus as primary immunotherapy'. Together they form a unique fingerprint.

  • Cite this